Abozaid Ghada Mohammed, Al-Omar Hussain Abdulrahman, Alrabiah Abdulaziz, AlMuaither Asma, McKnight Amy Jayne
Centre for Public Health, Institute of Clinical Sciences B, Royal Victoria Hospital, Queen's University Belfast School of Medicine, Dentistry and Biomedical Sciences, Belfast, United Kingdom.
Pharmacy Practice Department, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Front Pharmacol. 2025 May 1;16:1583477. doi: 10.3389/fphar.2025.1583477. eCollection 2025.
Rare diseases (RDs) present significant challenges worldwide, including Saudi Arabia (SA), where access to orphan drugs (ODs) is suboptimal. This study summarizes key insights from a multi-stakeholder workshop conducted in SA to explore and address challenges related to RD and OD accessibility. Strategies to improve the healthcare landscape for RDs in SA have also been recommended.
A 1-day workshop, conducted at the Saudi Health Council in Riyadh, SA on 5 June 2023, gathered stakeholders from the government, private sector, pharmaceutical industry, legislators, regulators, providers, payers, academia, and insurance companies. Through a series of presentations, educational sessions, and plenary discussions, participants examined the current landscape of RDs in SA, identified barriers to accessing ODs, and recommended strategies and initiatives to improve the accessibility, innovation, and sustainability of ODs.
The workshop highlighted key challenges recognized by a diverse group of 59 participants, including the absence of a national strategy, absent of local RDs and ODs definitions in the Saudi context, limited awareness and understanding of RDs among healthcare professionals, delayed diagnoses, scarcity of treatment and diagnosis centers for RDs, insufficient screening and prevention programs, regulatory hurdles in approving and importing ODs, and financial constraints. These challenges significantly impact patient access to ODs, imposing additional burdens on patients, families, healthcare systems, and society.
The recommended strategies to enhance RD and OD accessibility include multifaceted approaches, such as increasing medical education and awareness, accrediting and investing in expanding the number of centers of excellence for RD diagnosis and management, streamlining regulatory processes for OD approval and importation, fostering international collaborations for knowledge exchange and capacity building, and implementing national policies to improve the affordability and reimbursement of ODs. Stakeholder collaboration is crucial to overcome the accessibility challenges of RDs and ODs. The development of comprehensive national RD strategies ensures equitable resource allocation, a national RD registry, and infrastructure improvements. These measures are vital for ensuring equitable access to ODs and the efficient provision of healthcare services in SA.
罕见病在全球范围内都带来了重大挑战,沙特阿拉伯(简称沙特)也不例外,该国孤儿药的可及性欠佳。本研究总结了在沙特举办的一次多利益相关方研讨会的关键见解,此次研讨会旨在探讨并应对与罕见病及孤儿药可及性相关的挑战。同时还推荐了改善沙特罕见病医疗状况的策略。
2023年6月5日在沙特利雅得的沙特卫生委员会举办了一场为期一天的研讨会,召集了来自政府、私营部门、制药行业、立法者、监管机构、医疗服务提供者、支付方、学术界和保险公司的利益相关方。通过一系列演讲、教育课程和全体讨论,与会者审视了沙特罕见病的现状,确定了获取孤儿药的障碍,并推荐了改善孤儿药可及性、创新性和可持续性的策略与举措。
研讨会凸显了59名来自不同群体的参与者所认识到的关键挑战,包括缺乏国家战略、沙特语境下缺乏本地罕见病及孤儿药定义、医疗专业人员对罕见病的认识和了解有限、诊断延迟、罕见病治疗和诊断中心稀缺、筛查和预防项目不足、孤儿药审批和进口的监管障碍以及资金限制。这些挑战严重影响了患者获取孤儿药的机会,给患者、家庭、医疗系统和社会带来了额外负担。
推荐的提高罕见病及孤儿药可及性的策略包括多方面的方法,如加强医学教育和提高认识、对扩大罕见病诊断和管理卓越中心的数量进行认证和投资、简化孤儿药审批和进口的监管流程、促进国际合作以进行知识交流和能力建设,以及实施国家政策以提高孤儿药的可负担性和报销水平。利益相关方的合作对于克服罕见病和孤儿药的可及性挑战至关重要。制定全面的国家罕见病战略可确保公平的资源分配、建立国家罕见病登记处并改善基础设施。这些措施对于确保沙特公平获取孤儿药以及高效提供医疗服务至关重要。